trending Market Intelligence /marketintelligence/en/news-insights/trending/-qq6Q5FKfP7uhOUrdZvObA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Everstone to invest US$50M in KKR-backed Slayback Pharma

Key Credit Risk Factors When Assessing Banks In The Context Of COVID-19

Street Talk Episode 61 - Investors debate if U.S. banks have enough capital in post COVID world

You Down With PPP? Consider The Risks

Street Talk Episode 60 - You Down With PPP? Consider The Risks


Everstone to invest US$50M in KKR-backed Slayback Pharma

Asia-focused private equity firm Everstone Capital Asia Pte Ltd. agreed to invest up to US$50 million in a series B funding round in KKR & Co. Inc.-backed pharmaceutical company Slayback Pharma LLC.

Along with the investment, Everstone's managing directors Arjun Oberoi and Puncham Mukim will join Slayback's board.

The capital will be used to expand and accelerate Slayback's differentiated line of pharmaceutical products.

KKR invested US$60 million in Slayback in December 2016.